ProShares Ultra NASDAQ Biotechnology
BIB
BIB
28 hedge funds and large institutions have $23.7M invested in ProShares Ultra NASDAQ Biotechnology in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
48% less call options, than puts
Call options by funds: $5.84M | Put options by funds: $11.2M
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Holders
28
Holding in Top 10
1
Calls
$5.84M
Puts
$11.2M
Top Buyers
| 1 | +$4.05M | |
| 2 | +$1.95M | |
| 3 | +$1.06M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$443K |
| 5 |
BRC
Bell Rock Capital
Rehoboth Beach,
Delaware
|
+$81.8K |
Top Sellers
| 1 | -$1.38M | |
| 2 | -$818K | |
| 3 | -$711K | |
| 4 |
RIA
RPG Investment Advisory
Pleasanton,
California
|
-$648K |
| 5 |
Morgan Stanley
New York
|
-$469K |